UNSPSC 51123802: Meobentine

This classification denotes an antiarrhythmic agent with the molecular formula C11H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) T91E239Z1V, chemically known as 1-[(4-methoxyphenyl)methyl]-2,3-dimethylguanidine but more generally known as meobentine, which bears US NIH Compound Identifier 42765. European Medicines Agency schedules meobentine its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08743MIG.

Most nations, for tariff and trade purposes, schedule meobentine under HS 29252900 and SITC 51482. As of Q4 2014, MEOBENTINE remains US FDA's Preferred Term for this commodity. SMILES: CNC(=NC)NCC1=CC=C(C=C1)OC.

UNSPSC 51123802 Meobentine is a Commodity code covering pharmaceutical products supplied to state and local health and emergency-response systems. State and local governments procure under this code to stock emergency medications, pharmacy benefit programs, and institutional health-care delivery — acquiring specific drug formulations by National Drug Code, quantity, expiration requirements, and delivery timeline. The issuing bodies include city fire departments (Tampa Fire Rescue via the City of Tampa), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). Work under the code ranges from sealed-bid procurements for individual advanced life support medications to multi-state cooperative RFPs establishing master contracts with pharmaceutical manufacturers and authorized wholesalers.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000, requiring sealed bids for Labetalol, Epinephrine, Adenosine, and Diltiazem through the OpenGov eProcurement Portal; the contract includes a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 with a response deadline of March 26, 2026 to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, and administrative fee adherence; the resulting contracts become effective July 1, 2026 for two years.